Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01621009 · ClinicalTrials.gov registry record · Phase 4

Bupropion SR Plus Counseling for Smoking Cessation

A Phase 4 study of Smoking and Tobacco Dependence, sponsored by University of Wisconsin, Madison.

Completed
Registry status
Phase 4
Development phase
463
Enrollment target
1
Study location

NCT01621009: Completed Phase 4 study of Smoking and Tobacco Dependence, sponsored by University of Wisconsin, Madison.

NCT01621009 is a Phase 4 study of Smoking and Tobacco Dependence that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 463 participants, roughly in line with the 451-participant average among 123 other Smoking trials with a reported enrollment target. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01621009, a Phase 4 study of Smoking and Tobacco Dependence, has completed, sponsored by University of Wisconsin, Madison.

COMPLETED
Registry status
Phase 4
Development phase
463 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study was to determine if bupropion plus counseling was more effective than bupropion alone or counseling alone in helping smokers quit smoking.

Primary Outcome

No smoking, not even a puff, during the 7 days prior to the 6 month follow-up. Biochemically confirmed.

Interventions

  • DRUG Active bupropion + counseling
  • DRUG Active bupropion, No counseling
  • DRUG Placebo medication + counseling
  • DRUG Placebo medication, No counseling

Study Locations (1)

Wisconsin

  • UW Center for Tobacco Research and Intervention - Madison

Trial Details

FieldValue
Enrollment Target 463 participants
Start Date 2001-01
Est. Completion 2003-10
Phase Phase 4
University of Wisconsin, Madison

1,039 total trials

What the finished NCT01621009 record still lists

NCT01621009 is an interventional study that assigns participants to a tested intervention. The registered 463 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 451-participant average among 123 other Smoking trials with a reported enrollment target.

The record links to 2 conditions, with Smoking appearing as the primary indexed condition, and to 4 interventions - of which Active bupropion + counseling is the first listed.

NCT01621009 reports a single indexed study location in Wisconsin.

Frequently Asked Questions

What is clinical trial NCT01621009 about?

NCT01621009 is a clinical study titled "Bupropion SR Plus Counseling for Smoking Cessation". The purpose of this study was to determine if bupropion plus counseling was more effective than bupropion alone or counseling alone in helping smokers quit smoking.

What is the current status of trial NCT01621009?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 463 participants. The study started on 2001-01. Estimated completion is 2003-10.

What conditions does trial NCT01621009 study?

This clinical trial studies the following conditions: Smoking, Tobacco Dependence.

What interventions are being tested in trial NCT01621009?

The interventions under investigation include: Active bupropion + counseling (DRUG), Active bupropion, No counseling (DRUG), Placebo medication + counseling (DRUG), Placebo medication, No counseling (DRUG).

Who is sponsoring clinical trial NCT01621009?

This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01621009 being conducted?

This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01621009's enrollment target sits among peer trials

463 35th of 123 higher than 89 of 123 other Smoking trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Smoking trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04787744 · 464 participants · Phase 2

    Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer

  • NCT04855656 · 464 participants · Phase 1

    Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors

  • NCT06283927 · 464 participants

    The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302)

  • NCT06444295 · 464 participants · NA

    Testing the Impact of Thrive App Versions on Alcohol Use and Posttraumatic Stress After Recent Sexual Assault

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01621009, the US trial registry maintained by the National Library of Medicine. NCT01621009 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.